Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Tenaya Therapeutics Inc (TNYA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TNYA (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.14
1 Year Target Price $10.14
| 6 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 14.97% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 154.32M USD | Price to earnings Ratio - | 1Y Target Price 10.14 |
Price to earnings Ratio - | 1Y Target Price 10.14 | ||
Volume (30-day avg) 9 | Beta 3.02 | 52 Weeks Range 0.36 - 4.01 | Updated Date 08/15/2025 |
52 Weeks Range 0.36 - 4.01 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.94 |
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.18 | Actual -0.14 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -45.12% | Return on Equity (TTM) -85.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 94865070 | Price to Sales(TTM) - |
Enterprise Value 94865070 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.67 | Shares Outstanding 162976000 | Shares Floating 103227433 |
Shares Outstanding 162976000 | Shares Floating 103227433 | ||
Percent Insiders 0.72 | Percent Institutions 54.11 |
Upturn AI SWOT
Tenaya Therapeutics Inc
Company Overview
History and Background
Tenaya Therapeutics Inc. was founded in 2016 to develop therapies for heart disease. It is focused on addressing the underlying causes of heart disease through gene therapy and precision medicine.
Core Business Areas
- Gene Therapy Programs: Developing adeno-associated virus (AAV) based gene therapies to deliver genes to correct underlying defects in heart muscle cells.
- Precision Medicine: Using human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) to identify and validate novel drug targets and develop personalized therapies for heart disease.
Leadership and Structure
The leadership team consists of seasoned biotechnology executives with expertise in drug development and commercialization. The organizational structure is typical of a clinical-stage biotech company, with research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- TN-201 (MYBK-001): A gene therapy candidate for hypertrophic cardiomyopathy (HCM) caused by mutations in the MYBPC3 gene. It is in Phase 1 clinical trials. Competitors include pharmaceutical companies researching therapies for hypertrophic cardiomyopathy. No definitive market share data available at this early clinical stage. The competitors include Bristol Myers Squibb (BMS) with Mavacamten for symptomatic HCM.
- TN-301: A small molecule HDACI inhibitor candidate for heart failure with preserved ejection fraction (HFpEF) and in preclinical studies. No definitive market share data available. Competitors include larger pharmaceutical companies developing drugs for heart failure. Competitors include Cytokinetics (CYTK) which has clinical trials ongoing for a heart failure drug.
Market Dynamics
Industry Overview
The cardiovascular disease market is large and growing due to aging populations and increasing prevalence of risk factors such as obesity and diabetes. There is a significant unmet need for therapies that address the underlying causes of heart disease.
Positioning
Tenaya Therapeutics is positioned as an innovator in gene therapy and precision medicine for heart disease. Its competitive advantage lies in its focus on addressing the underlying genetic causes of heart disease and its use of iPSC-CM technology to identify novel drug targets.
Total Addressable Market (TAM)
The TAM for heart failure and cardiomyopathies is estimated to be in the tens of billions of dollars globally. Tenaya is positioned to capture a portion of this market through its gene therapy and precision medicine programs.
Upturn SWOT Analysis
Strengths
- Novel gene therapy and precision medicine platform
- Strong scientific team
- Focus on addressing unmet needs in heart disease
- Collaboration with leading academic institutions
Weaknesses
- Early-stage clinical programs
- Reliance on funding
- Small size relative to competitors
- High risk associated with drug development
Opportunities
- Potential for breakthrough therapies
- Expansion into new indications
- Partnerships with larger pharmaceutical companies
- Advancements in gene therapy technology
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
- Adverse events observed in their clinical trials
Competitors and Market Share
Key Competitors
- MYOK
- BMS
- CYTK
Competitive Landscape
Tenaya faces competition from established pharmaceutical companies and other biotech companies developing therapies for heart disease. Its advantage lies in its novel gene therapy and precision medicine platform. The other competitors have drugs on the market or are in late stage trials.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily driven by advancing its clinical programs and securing funding.
Future Projections: Future growth depends on clinical trial success, regulatory approvals, and commercialization of its therapies. Analyst estimates vary widely depending on the success of its programs.
Recent Initiatives: Recent initiatives include advancing clinical trials for TN-201, progressing preclinical programs, and establishing collaborations with strategic partners.
Summary
Tenaya Therapeutics is a high-risk, high-reward biotech company focused on developing innovative therapies for heart disease. Its gene therapy and precision medicine programs have the potential to address unmet needs in the field. However, the company faces significant challenges, including clinical trial risk, regulatory hurdles, and competition from established pharmaceutical companies. Success hinges on positive clinical trial results and securing additional funding.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, press releases, analyst reports, industry publications.
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information contained herein is not guaranteed to be accurate or complete. Investments in biotech companies are highly speculative and involve significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tenaya Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2021-07-30 | CEO, Interim Principal Financial Officer & Director Mr. Faraz Ali M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 97 | |
Full time employees 97 | |||
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. The company develops its products through gene editing, cellular regeneration, gene silencing, and gene addition. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.